Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated
Executive Summary
Patient-reported outcomes indicate patients don’t see itch as a major quality-of-life factor. Intercept also reports that adding earlier-stage patients to review of OCA shows better data on resolving NASH.
You may also be interested in...
Terns Says Phase IIa Data Show Superior NASH Safety Profile In FXR Class
TERN-101 showed a superior safety and tolerability profile for lipid levels and pruritis compared to other FXR agonists in a mid-stage study. Terns is now looking to a NASH combo study with its THR beta agonist.
Terns Raises $87m More For NASH R&D, Including Lilly Equity Purchase
In its third venture funding round, Terns adds backing from Deerfield in addition to Lilly’s investment. It licensed three non-alcoholic steatohepatitis candidates from the big pharma in 2018.
Payer KOL Says Expect “Levers” To Limit Early Uptake Of NASH Drugs
Liver health key opinion leaders say pre-authorization, requirements for biopsies or sicker patients could limit early uptake of NASH drugs. Intercept’s OCA, Genfit’s elafibranor both seen as likely combo therapy components.